



About Medicomp

Founded in 1981, Medicomp designs, develops and provides advanced cardiac monitoring products and services using the most sophisticated and reliable ambulatory heart-monitoring systems in the world. Since its inception, Medicomp has been a technology leader in the cardiac telemedicine industry – pioneering leading edge products and services, and developing new applications that result in better clinical outcomes. In December 2000, Medicomp Inc. became a wholly owned subsidiary of United Therapeutics, a highly successful and publicly traded biotechnology corporation.

Medicomp is unique in that it develops and produces the products and systems it uses for the provision of its services. Medicomp's asymptomatic diagnostic technologies are widely regarded as the most advanced in the industry, and they are therefore entrusted by physicians to provide cardiac monitoring services to thousands of patients nationwide.

Medicomp is further distinguished by being led by a physician, Dr. Daniel Balda. Dr. Balda is a Cornell-educated engineer who completed his medical training at the University of Florida. Serving as President and COO, his years of experience in ECG technologies guide Medicomp with a physician's perspective in caring for patients.

The heart of Medicomp's proprietary technology is the most comprehensive system for diagnosing arrhythmia in an ambulatory environment. Medicomp's ECG monitors employ artificial intelligence operating in real-time, including patented p-wave analysis that confirms atrial activity and delivers research-grade AF detection. Compared to other systems, Medicomp's devices are proven to deliver faster and more accurate diagnosis of cardiac abnormalities, and are noted for being able to detect even short runs of asymptomatic AF where other monitors fail.

Today Medicomp is one of the fastest growing cardiac monitoring service providers in the United States. This success is due to the proven superiority of Medicomp technology, Medicomp's dedicated employees, and their commitment to service excellence.

Medicomp is continuing to drive the science of remote patient monitoring, and is helping to shape the future of cardiac telemedicine as it evolves toward intelligent devices which enable earlier and more accurate diagnosis. We invite you to visit our website www.medicompinc.com and take a look at some of our proud Industry Firsts and learn more about our Diogenes™ algorithm.

*For financial information, please contact our parent company:
United Therapeutics Corporation
Silver Spring, MD 20910
www.unither.com*

